Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IA-GRACE-IgANT: Platform Trial in IgA Nephropathy
NCT06676384Phase 4Recruiting
- Sponsor
- Christian Medical College, Vellore
- Start
- Feb 2025
- Primary completion
- Aug 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of prednisolone, EPI-EE, mycophenolate mofetil and hydroxychloroquine in IgA nephropathy (IgAN) (5 arms), sponsored by Christian Medical College, Vellore. Primary endpoint: Mean change in annualized eGFR slope at 24 months. Started Feb 2025; status: recruiting.
02
Drugs
prednisoloneEPI-EEmycophenolate mofetilhydroxychloroquine
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06676384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676384.